spironolactone has been researched along with Nephrosclerosis in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 7.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 3.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klanke, B | 2 |
| Cordasic, N | 1 |
| Hartner, A | 2 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 2 |
| Fujii, H | 1 |
| Nakahama, H | 1 |
| Yoshihara, F | 1 |
| Nakamura, S | 1 |
| Inenaga, T | 1 |
| Kawano, Y | 1 |
| Takahashi, T | 1 |
| Ono, H | 1 |
| Ono, Y | 1 |
| Ishimitsu, T | 1 |
| Matsuoka, H | 1 |
| Westhoff, JH | 1 |
| Steinbach, MP | 1 |
| Amann, K | 1 |
| Melk, A | 1 |
4 other studies available for spironolactone and Nephrosclerosis
| Article | Year |
|---|---|
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Drug Therapy | 2005 |
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; | 2007 |
Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Ag | 2008 |